GlassScriptPhysician profile
Breck Dakin
NPI 1316611585
$9,395.14
in general payments reported to CMS, 2019-2025
18 companies · $1,450 in 2025
The $1,450 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $178 · 2022: $3,023 · 2023: $1,796 · 2024: $2,948 · 2025: $1,450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,100 · Travel and Lodging: $997 · Education: $97.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,099.74 |
| Travel and Lodging | $996.62 |
| Education | $97.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,953.62 | 2021-2025 | Precision7, Total30, Rocklatan |
| Bausch & Lomb Americas INC. | $1,847.86 | 2022-2025 | Infuse, Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $615.22 | 2021-2025 | Cequa |
| Oyster Point Pharma, INC. | $606.96 | 2022-2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $396.65 | 2021-2023 | |
| Biotissue Holdings INC. | $342.77 | 2022-2024 | |
| Tarsus Pharmaceuticals, INC. | $311.35 | 2024-2025 | Xdemvy |
| Coopervision INC. | $234.87 | 2022-2025 | Misight Contact Lens, Clariti Contact Lens, Myday Contact Lens |
| Mallinckrodt Hospital Products INC. | $233.57 | 2022-2024 | Acthar |
| Johnson & Johnson Vision Care, INC. | $229.78 | 2024-2025 | |
| Sight Sciences, INC. | $148.42 | 2023 | Omni Surgical System |
| Allergan, INC. | $114.59 | 2022 | |
| Thea Pharma INC. | $95.85 | 2022-2023 | Iyuzeh |
| Horizon Therapeutics Plc | $79.73 | 2023 | Tepezza |
| Glaukos Corporation | $79.36 | 2022-2024 | Ce-Marked Kxla System |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $76.14 | 2022-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $16.12 | 2022 | |
| Tearlab Corp | $12.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Breck Dakin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.